$1,043.06
Value $102B
EQIX and SBRA stock compared: price, dividend, valuation and results, from SEC filings.
$1,043.06
Value $102B
$20.35
Value $5.1B
Equinix (EQIX) has a market value of $102B and Sabra Health Care REIT (SBRA) $5.1B. Over the last year, with dividends, EQIX moved +35.6% and SBRA +17.5%. The P/E is 62.2 for EQIX and 71.8 for SBRA. Dividend yield: EQIX 1.93%, SBRA 5.90%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
EQIX$102B
SBRA$5.1B
EQIX is 20 times SBRA
Revenue, 12 months
EQIX$10.1B
SBRA$919M
EQIX is 11 times SBRA
Net income, 12 months
EQIX$1.6B
SBRA$72M
EQIX is 23 times SBRA
Operating margin
EQIX22.5%
SBRA–
ROIC
EQIX5.9%
SBRA1.0%
4.9 points apart
P/E
EQIX62.2
SBRA71.8
SBRA is 1.2 times EQIX
Dividend yield
EQIX1.9%
SBRA5.9%
4.0 points apart
5-year return
EQIX+44.4%
SBRA+106.9%
62.5 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
EQIX+44.4%
SBRA+106.9%
| Period | EQIXWith dividends | SBRAWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +35.6%Price +32.8% | +17.5%Price +9.1% |
| 3 years since November 16, 2023 | +41.6%+12.3% a yearPrice +33.7% | +75.3%+20.6% a yearPrice +43.1% |
| 5 years since November 15, 2021 | +44.4%+7.6% a yearPrice +30.7% | +106.9%+15.6% a yearPrice +40.4% |
| 10 years since November 16, 2016 | +274.4%+14.1% a yearPrice +210.5% | +112.6%+7.8% a yearPrice -4.6% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
EQIXEquinixSBRASabra Health Care REIT
| Price | $1,043.06 | $20.35 |
|---|---|---|
| Market value | $102B | $5.1B |
| Enterprise value (EV) | $124B | $7.5B |
| P/E | 62.2 | 71.8 |
| P/E, 5-year median | 78.1 | – |
| P/B | 7.1 | 1.8 |
| EV/EBIT | 54.8 | 115.8 |
| Free cash flow yield | – | – |
| Revenue, 12 months | $10.1B | $919M |
|---|---|---|
| Net income, 12 months | $1.6B | $72M |
| Free cash flow, 12 months | -$1.7B | – |
| Earnings per share, 12 months | $16.65 | $0.28 |
| Revenue growth, year on year | 5.4% | 10.2% |
| Revenue growth a year, past | +9.0%over 5 years | +5.3%over 5 years |
| EPS growth a year, past | +26.9%over 5 years | -0.9%over 5 years |
| Gross margin | 51.6% | – |
|---|---|---|
| Operating margin | 22.5% | – |
| Net margin | 16.4% | 7.8% |
| ROIC | 5.9% | 1.0% |
| ROE | 11.5% | 2.6% |
| Cash | $3.6B | $36M |
|---|---|---|
| Total debt | $26.6B | $2.4B |
| Net debt / EBITDA | 5.0 | 9.5 |
| Interest cover | 3.8× | 0.6× |
| Dividend yield | 1.9% | 5.9% |
|---|---|---|
| Dividend per share, 12 months | $20.17 | $1.20 |
| Dividend growth a year, past | +12.0%over 5 years | -2.3%over 5 years |
| Buyback yield | – | – |
| Shareholder yield | 1.9% | 5.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Equinix ($102B) is about 20.0 times Sabra Health Care REIT ($5.1B), at today's prices.
Since November 16, 2016, EQIX's price moved +210.5% and SBRA's -4.6%. With dividends: EQIX +274.4% (+14.1% a year), SBRA +112.6% (+7.8% a year). Past returns do not predict future ones.
The dividend yield at today's price is 1.93% for Equinix and 5.90% for Sabra Health Care REIT. Over the last twelve months they paid $20.17 and $1.20 per share.
At today's price, the P/E is 62.2 for EQIX and 71.8 for SBRA. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 16.4% for Equinix and 7.8% for Sabra Health Care REIT, and the operating margin 22.5% and –. Revenue was $10.1B and $919M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.